Understanding the Market | JIUYUAN GENE surged nearly 24% in the late trading session and is expected to release its performance report next Monday, with plans to submit a new drug application for semaglutide to Brazil and other countries within the year
I'm PortAI, I can summarize articles.
JIUYUAN GENE rose nearly 24% in the late trading session, closing at HKD 15.28, with a transaction volume of HKD 41.215 million. The company will hold a board meeting on August 18 to approve its interim results and plans to submit a new drug application for Semaglutide in Brazil and Saudi Arabia within 2025. JIUYUAN GENE's market layout for weight loss indications will expand accessibility through collaborations with in-hospital markets and e-commerce platforms, and it has signed exclusive licensing agreements for overseas markets with other pharmaceutical companies
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments